KD Logo

Nektar Therapeutics [NKTR] Chief R&D Officer makes an insider sale of 6,866 shares worth 8,788.

The buying and selling of stock by a company’s insider give investors a sense that the stock will rise or fall in the future. Nektar Therapeutics shares valued at $8,788 were sold by Zalevsky Jonathan on Aug 19 ’24. At $1.28 per share, Zalevsky Jonathan sold 6,866 shares. The insider’s holdings dropped to 250,804 shares worth approximately $0.33 million following the completion of this transaction.

3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free
Sponsored

Also, Wilson Mark Andrew sold 5,651 shares, netting a total of over 7,233 in proceeds. Following the sale of shares at $1.28 each, the insider now holds 225,263 shares.

Before that, ROBIN HOWARD W had sold 14,881 shares from its account. In a trade valued at $19,048, the President & CEO traded Nektar Therapeutics shares for $1.28 each. Upon closing the transaction, the insider’s holdings decreased to 14,881 shares, worth approximately $1.1 million.

Analysts at Rodman & Renshaw started covering the stock with ‘”a Buy”‘ outlook in a report released in late June. Earlier on November 09, 2023, TD Cowen upgraded its rating. Their new recommendation was “an Outperform” for NKTR stock which previously was a “a Market perform”.

Analyzing NKTR Stock Performance

During the last five days, there has been a surge of approximately 17.12%. Over the course of the year, Nektar Therapeutics shares have jumped approximately 130.09%. Shares of the company reached a 52-week high of $1.9280 on 05/13/24 and a 52-week low of $0.4800 on 01/18/24. A 50-day SMA is recorded $1.2457, while a 200-day SMA reached $1.1045. Nevertheless, trading volume fell to 1.2 million shares from 2.3 million shares the previous day.

Support And Resistance Levels for Nektar Therapeutics (NKTR)

According to the 24-hour chart, there is a support level at 1.2633, which, if violated, would cause prices to drop to 1.2267. In the upper region, resistance lies at 1.3333. The next price resistance is at 1.3667. RSI (Relative Strength Index) is 54.50 on the 14-day chart, showing neutral technical sentiment. Moving Average Convergence Divergence (MACD) is at 0.0614, which suggests the price will decrease in the coming days. Percent R is at 30.91%, indicating low price movement. Stochastics %K at holding indicates that the stock is to be held.

Most Popular